VEGFA and glioblastoma: In 2009, the anti‐VEGF monoclonal antibody bevacizumab received accelerated United States Food and Drug Administration (FDA) approval as a single agent for the treatment of recurrent glioblastoma.6 Approval of bevacizumab was based on durable objective response rates (ORRs) and 6‐month progression‐free survival (PFS) data obtained from two single‐arm phase 2 studies.